ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2025
Molecular features reflect clinical outcomes after recurrence in medulloblastoma: a single-institution experience.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe relationship between molecular features and clinical courses of medulloblastoma at onset has been recently reported; however, data in a recurrent setting are scarce.
methodsWe collected medical records, analyzed molecular genetic data of eight patients with medulloblastoma that recurred between 2014 and 2023 in our institution, and retrospectively analyzed the clinical course. Molecular classification and copy number data were obtained using the Illumina Methylation EPIC array®.
resultsThe pathological findings were classic and large cell/anaplastic in six and two cases, respectively. The molecular classifications were sonic hedgehog, Group 3, and Group 4 in two, two, and four cases, respectively. Among Group 3/4 cases, two were subclassified as subclass II and III, which were regarded as poor prognostic. A copy number abnormality of MYC/MYCN amplification was observed in three cases. The cases with poor prognostic molecular features showed worse prognosis than that of others (the median durations from the first diagnosis to recurrence 8.5 months vs. 60 months; p = 0.02857, and the median survival time from recurrent diagnosis 3.5 months vs. 42 months; p = 0.00673). Regarding treatment response, no cases with poor prognostic molecular features showed tumor shrinkage with chemotherapy and/or radiation therapy at relapse, except for one case. In contrast, three cases with non-poor prognostic molecular features have been able to control the disease status for more than 2 years.
conclusionThe clinical course of recurrent medulloblastoma depends on molecular features. Salvage treatment effectiveness should be evaluated on the basis of molecular genetic background information.
Indexed as
Identifiers
40987845What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.